Patient and disease characteristics and summary of previous treatment and Pola-BR treatment intent
| Characteristic . | All patients (N = 133) . | Stand-alone therapy (n = 78) . | Bridge to CAR T-cell therapy (n = 40) . |
|---|---|---|---|
| Median age, y (range) | 72 (18-88) | 75 (41-88) | 66.5 (29-82) |
| Sex | |||
| Male | 87 (65.4) | 54 (69.2) | 23 (57.5) |
| Female | 46 (34.6) | 24 (30.8) | 17 (42.5) |
| ECOG PS | |||
| 0-1 | 90 (67.7) | 46 (59.0) | 31 (77.5) |
| ≥2 | 40 (30.1) | 31 (39.7) | 7 (17.5) |
| Unknown | 3 (2.3) | 1 (1.3) | 2 (5) |
| Diagnosis | |||
| DLBCL (transformed low-grade lymphoma) | 31 (23.3) | 17 (21.8) | 12 (30) |
| DLBCL, not otherwise specified | 78 (58.6) | 48 (61.5) | 23 (57.5) |
| Double-hit or triple-hit DLBCL | 14 (10.5) | 9 (11.5) | 4 (10.0) |
| Posttransplant lymphoproliferative disorder | 1 (0.8) | 1 (1.3) | 0 |
| Plasmablastic lymphoma | 2 (1.5) | 1 (1.3) | 0 |
| Primary cutaneous DLBCL, leg type | 1 (0.8) | 1 (1.3) | 0 |
| Primary mediastinal large B-cell lymphoma | 4 (3.0) | 0 | 1 (2.5) |
| T-cell rich/histiocyte rich large B-cell lymphoma | 1 (0.8) | 1 (1.3) | 0 |
| IPI score | |||
| 0-2 | 39 (29.3) | 21 (26.9) | 10 (25) |
| ≥3 | 86 (64.7) | 56 (71.8) | 25 (62.5) |
| Unknown | 8 (6.0) | 1 (1.3) | 5 (12.5) |
| Bulky disease (>7.5 cm) | |||
| Yes | 29 (21.8) | 22 (28.2) | 2 (5.0) |
| No | 73 (54.9) | 53 (67.9) | 10 (25.0) |
| Unknown | 31 (23.3) | 3 (3.8) | 28 (70.0) |
| Cell of origin | |||
| Non-germinal center | 40 (30.1) | 27 (34.6) | 7 (17.5) |
| Germinal center B-cell | 45 (33.8) | 37 (47.4) | 4 (10.0) |
| Unknown | 48 (36.1) | 14 (17.9) | 29 (72.5) |
| Median lines of previous therapy (range) | 2 (1-6) | 1 (1-6) | 2 (2-4) |
| 1 | 45 (33.8) | 43 (55.1) | 1 (2.5) |
| 2 | 25 (18.8) | 13 (16.7) | 25 (62.5) |
| ≥3 | 34 (25.6) | 20 (25.6) | 14 (35.0) |
| Unknown | 2 (1.5) | 2 (2.6) | 0 |
| Duration of response of last treatment, mo | |||
| <12 | 103 (77.4) | 53 (67.9) | 36 (90.0) |
| >12 | 23 (17.3) | 20 (25.6) | 3 (7.5) |
| Unknown | 7 (5.3) | 5 (6.4) | 1 (2.5) |
| Refractory to last line of treatment | |||
| Yes | 91 (68.4) | 45 (57.7) | 33 (82.5) |
| No | 42 (31.6) | 33 (42.3) | 7 (17.5) |
| Previous SCT | |||
| Yes | 6 (4.5) | 0 | 6 (15.0) |
| No | 127 (95.5) | 78 (100) | 34 (85.0) |
| Previous CAR T-cell therapy | |||
| Yes | 16 (12.0) | 6 (7.7) | 0 |
| No | 117 (88.0) | 72 (92.3) | 40 (100) |
| Treatment intent | |||
| Bridge to auto-SCT | 5 (3.8) | 0 | 0 |
| Bridge to CAR T-cell therapy | 40 (30.1) | 0 | 40 (100.0) |
| Bridge to allo-SCT | 8 (6.0) | 0 | 0 |
| Stand-alone (no planned SCT or CAR T-cell therapy) | 78 (58.6) | 78 (100.0) | 0 |
| Unknown | 2 (1.5) | 0 | 0 |
| Primary reason for SCT ineligibility | |||
| Age | 43 (55.1) | ||
| Comorbidities | 17 (21.8) | ||
| Failed previous transplantation | 1 (1.3) | ||
| Insufficient CD34+ cells collected | 1 (1.3) | ||
| Insufficient response to salvage therapy | 14 (17.9) | ||
| PS | 1 (1.3) | ||
| Unknown | 1 (1.3) |
| Characteristic . | All patients (N = 133) . | Stand-alone therapy (n = 78) . | Bridge to CAR T-cell therapy (n = 40) . |
|---|---|---|---|
| Median age, y (range) | 72 (18-88) | 75 (41-88) | 66.5 (29-82) |
| Sex | |||
| Male | 87 (65.4) | 54 (69.2) | 23 (57.5) |
| Female | 46 (34.6) | 24 (30.8) | 17 (42.5) |
| ECOG PS | |||
| 0-1 | 90 (67.7) | 46 (59.0) | 31 (77.5) |
| ≥2 | 40 (30.1) | 31 (39.7) | 7 (17.5) |
| Unknown | 3 (2.3) | 1 (1.3) | 2 (5) |
| Diagnosis | |||
| DLBCL (transformed low-grade lymphoma) | 31 (23.3) | 17 (21.8) | 12 (30) |
| DLBCL, not otherwise specified | 78 (58.6) | 48 (61.5) | 23 (57.5) |
| Double-hit or triple-hit DLBCL | 14 (10.5) | 9 (11.5) | 4 (10.0) |
| Posttransplant lymphoproliferative disorder | 1 (0.8) | 1 (1.3) | 0 |
| Plasmablastic lymphoma | 2 (1.5) | 1 (1.3) | 0 |
| Primary cutaneous DLBCL, leg type | 1 (0.8) | 1 (1.3) | 0 |
| Primary mediastinal large B-cell lymphoma | 4 (3.0) | 0 | 1 (2.5) |
| T-cell rich/histiocyte rich large B-cell lymphoma | 1 (0.8) | 1 (1.3) | 0 |
| IPI score | |||
| 0-2 | 39 (29.3) | 21 (26.9) | 10 (25) |
| ≥3 | 86 (64.7) | 56 (71.8) | 25 (62.5) |
| Unknown | 8 (6.0) | 1 (1.3) | 5 (12.5) |
| Bulky disease (>7.5 cm) | |||
| Yes | 29 (21.8) | 22 (28.2) | 2 (5.0) |
| No | 73 (54.9) | 53 (67.9) | 10 (25.0) |
| Unknown | 31 (23.3) | 3 (3.8) | 28 (70.0) |
| Cell of origin | |||
| Non-germinal center | 40 (30.1) | 27 (34.6) | 7 (17.5) |
| Germinal center B-cell | 45 (33.8) | 37 (47.4) | 4 (10.0) |
| Unknown | 48 (36.1) | 14 (17.9) | 29 (72.5) |
| Median lines of previous therapy (range) | 2 (1-6) | 1 (1-6) | 2 (2-4) |
| 1 | 45 (33.8) | 43 (55.1) | 1 (2.5) |
| 2 | 25 (18.8) | 13 (16.7) | 25 (62.5) |
| ≥3 | 34 (25.6) | 20 (25.6) | 14 (35.0) |
| Unknown | 2 (1.5) | 2 (2.6) | 0 |
| Duration of response of last treatment, mo | |||
| <12 | 103 (77.4) | 53 (67.9) | 36 (90.0) |
| >12 | 23 (17.3) | 20 (25.6) | 3 (7.5) |
| Unknown | 7 (5.3) | 5 (6.4) | 1 (2.5) |
| Refractory to last line of treatment | |||
| Yes | 91 (68.4) | 45 (57.7) | 33 (82.5) |
| No | 42 (31.6) | 33 (42.3) | 7 (17.5) |
| Previous SCT | |||
| Yes | 6 (4.5) | 0 | 6 (15.0) |
| No | 127 (95.5) | 78 (100) | 34 (85.0) |
| Previous CAR T-cell therapy | |||
| Yes | 16 (12.0) | 6 (7.7) | 0 |
| No | 117 (88.0) | 72 (92.3) | 40 (100) |
| Treatment intent | |||
| Bridge to auto-SCT | 5 (3.8) | 0 | 0 |
| Bridge to CAR T-cell therapy | 40 (30.1) | 0 | 40 (100.0) |
| Bridge to allo-SCT | 8 (6.0) | 0 | 0 |
| Stand-alone (no planned SCT or CAR T-cell therapy) | 78 (58.6) | 78 (100.0) | 0 |
| Unknown | 2 (1.5) | 0 | 0 |
| Primary reason for SCT ineligibility | |||
| Age | 43 (55.1) | ||
| Comorbidities | 17 (21.8) | ||
| Failed previous transplantation | 1 (1.3) | ||
| Insufficient CD34+ cells collected | 1 (1.3) | ||
| Insufficient response to salvage therapy | 14 (17.9) | ||
| PS | 1 (1.3) | ||
| Unknown | 1 (1.3) |
All data are presented as No. (%) unless otherwise stated.
ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index.